Jul 01,2020

NICE Partners with Flatiron Health to Develop Real-World Evidence Research Methodologies

The National Institute for Health and Care Excellence (NICE) is partnering with Flatiron Health, an oncology research and technology company, to explore how real-world evidence (RWE) can inform the clinical and cost effectiveness of health technologies. Flatiron Health and NICE experts will together conduct research that leverages Flatiron expertise and evidence generated from Flatiron’s electronic-health-record (EHR)-derived database; no individual patient data will be shared. An initial research project already underway will compare survival estimates from clinical trials to survival data observed in actual patient records to evaluate opportunities to reduce uncertainty in the estimation of long-term outcomes.

COLLABORATION PARTNERSHIP

#r&d

#rwe

#rwd

View Analyst & Ambassador Comments
Go to original news
Oct 13,2020

Harvard Pilgrim Health Care Partners With OncoHealth for Oncology Benefits Management

OncoHealth, the leading digital health company focused on the physical, mental and financial complexities of cancer care, providers, and patients with solutions that are purpose-built for oncology, has announced a multi-year partnership with Harvard Pilgrim Health Care. Harvard Pilgrim’s selection of OncoHealth’s utilization management solution was based on its capacity to leverage both provider generated real-world data and health plan claims data in making evidence-based decisions quickly, as well as its analytics software, which normalizes data into novel dashboards to better manage trends in drug utilization, spend and population health of oncology members.

COLLABORATION PARTNERSHIP

#insurance

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 18,2020

Launch of a new R&D program to extend the Theraxium platform supported by a loan from BPIFrance

Voluntis (Euronext Paris, Ticker: VTX – ISIN: FR0004183960) a leader in digital therapeutics, today announced the launch of a new R&D program to advance the capabilities of its Theraxium platform. It also announced a new loan obtained from Bpifrance to support its innovation program. This €1 million loan has a term of six years and two months. This term includes a deferred principal repayment period of 14 months followed by a straight-line repayment period over 5 years. The first installment will be payable on March 31, 2022 and the last installment payable on December 31, 2026.

PRODUCT

#ai/software

#platform

#rwd

View Analyst & Ambassador Comments
Go to original news
Jan 24,2019

Real-World Data based on Kaiku Health Immune Checkpoint Inhibitor Module published in Journal of Cancer Research and Clinical Oncology

Kaiku Health, Oulu University Hospital and Docrates Cancer Center have published first data on the symptoms reported by cancer patients receiving immune checkpoint inhibitor (ICI) therapies in a real-world setting. This study shows that utilizing digital symptom tracking is feasible in better engaging patients in symptom self-reporting during ICI treatments. This helps in gaining a more comprehensive understanding on the onset and presence of immune-related adverse events.

CLINICAL STUDY

#ml

#rwd

View Analyst & Ambassador Comments
Go to original news
Jan 01,2019

Flatiron Signs Definitive Agreement to Acquire the Assets of American Family Archives & Chronicles, Inc.

Flatiron Health has entered into a definitive agreement to acquire the assets developed by American Family Archives & Chronicles, Inc (AFAC). Flatiron has been working with AFAC for over three years, and they believe that the addition of their team will help Flatiron continue to develop a high-quality, comprehensive mortality dataset.

COLLABORATION MERGERS & ACQUISITION

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Feb 01,2019

The FDA and Flatiron Health Expand Real-World Data Cancer Research Collaboration

Flatiron Health and the Information Exchange and Data Transformation (INFORMED) Program at the U.S. Food and Drug Administration (FDA) today announced a two-year renewal and expansion of their research collaboration agreement. The collaboration, which began in 2016, has enabled the FDA to better understand how real-world evidence (RWE), derived from de-identified patient datasets curated from electronic health records, can support regulatory decision-making.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Aug 01,2019

Flatiron Health Announces Three Publications Studying a Feasible, Reliable, Scalable and Meaningful Real-World Progression Endpoint for Oncology Research

Today, Flatiron Health announced a series of three research publications that developed and evaluated a new approach to capture when a patient’s cancer has worsened based on information contained in the electronic health record (EHR). These manuscripts illustrate the potential impact for research conducted from data collected as part of routine clinical care (real-world data).

CLINICAL STUDY

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Sep 24,2019

Pfizer and Flatiron Health Announce Expanded Strategic Collaboration to Unlock Power of Real-World Evidence in Oncology

Pfizer and Flatiron Health today announced an expanded strategic collaboration to further integrate and increase the use of real-world data in Pfizer’s development of innovative targeted cancer medicines. Under the terms of the agreement, Pfizer will draw on de-identified, real-world datasets and analytical expertise from Flatiron Health to inform development strategies and activities for a number of clinical development projects across major tumor types, as well as jointly explore other innovative ways to drive clinical development innovation with real-world data.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#platform

View Analyst & Ambassador Comments
Go to original news
Dec 12,2019

Research shows that machine learning can be used to predict the onset and continuity of symptoms on patients receiving immune checkpoint inhibitor therapies

Kaiku Health and Oulu University Hospital have jointly published a research investigating the feasibility of machine learning in predicting symptoms of patients undergoing Immune Checkpoint Inhibitor (ICI) treatments. The study is the first of its kind and the results were published at the ESMO Immuno-Oncology Congress 2019 in Geneva on December 12. The results indicate that machine learning-based modeling of patient-reported symptom data on ICI treated cancer patients can predict the onset and continuity of symptoms related to ICI toxicities. The best performance considering all metrics was found for shortness of breath, joint pain, cough and fatigue. Importantly, all 14 symptom prediction models performed at a good level.

CLINICAL STUDY

#rwd

#ml

View Analyst & Ambassador Comments
Go to original news
Nov 21,2018

Syntropy to Unlock the Value of Scientific Data in Fight to End Cancer

Merck and software company Palantir Technologies, today announced their intent to form a joint venture under the brand name Syntropy. Research institutions around the world are generating a rapidly growing amount of biomedical data, but much of it is trapped in silos within and between institutions. Today, this critical data is often inaccessible to the scientists and clinicians who need it to advance their work. Syntropy aims to unlock the value of this untapped data, enabling the world's leading experts to collaborate in the fight against cancer and many other diseases.

COLLABORATION PARTNERSHIP

#product & service

#rwd

View Analyst & Ambassador Comments
Go to original news
Subscribe to RWD